PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today unveiled plans to expand its pipeline of development compounds, following recent news announcing favorable research outcomes and accelerated development of the Company’s ‘polyphenol’ class of compounds for type-2 diabetes.
